

## InDex Pharmaceuticals updates shareholders list

**October 28, 2019 – InDex Pharmaceuticals Holding AB (publ) today announced that the list of shareholders has been updated on the homepage with information as of October 18, 2019.**

The 15 largest shareholders in InDex Pharmaceuticals Holding AB (publ) were per October 18, 2019:

<b>Shareholder</b>	<b>Number of shares</b>	<b>Ownership %</b>	<b>Votes %</b>
SEB Venture Capital	12 994 367	14.6	14.6
Stiftelsen Industrifonden	12 865 296	14.5	14.5
Linc AB	8 875 650	10.0	10.0
Fjärde AP-fonden	6 400 000	7.2	7.2
Avanza Pension	3 338 907	3.8	3.8
Staffan Rasjö	3 124 718	3.5	3.5
Originat AB	2 700 000	3.0	3.0
SEB Life International	2 321 225	2.6	2.6
Skandinaviska Enskilda Banken SA	2 300 000	2.6	2.6
Nordnet Pensionsförsäkring AB	2 001 604	2.3	2.3
SEB Stiftelsen	1 785 714	2.0	2.0
Ponderus Invest AB	1 000 000	1.1	1.1
Rune Pettersson	980 081	1.1	1.1
ABN AMRO Global Custody Services NV	913 955	1.0	1.0
Ålandsbanken	891 735	1.0	1.0

### **For more information:**

Peter Zerhouni, CEO

Phone: +46 8 508 847 35

E-mail: [peter.zerhouni@indexpharma.com](mailto:peter.zerhouni@indexpharma.com)

### **InDex Pharmaceuticals in brief**

InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company's lead asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe ulcerative colitis - a debilitating, chronic inflammation of the large intestine. InDex has also developed a platform of patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in treatment of various immunological diseases.

InDex is based in Stockholm, Sweden. The company's shares (ticker INDEX) are traded on Nasdaq First North Growth Market Stockholm. Redeye AB with e-mail [certifiedadviser@redeye.se](mailto:certifiedadviser@redeye.se) and phone number +46 8 121 576 90 is the company's Certified Adviser. For more information, please visit [www.indexpharma.com](http://www.indexpharma.com)

### **Publication**

The information was submitted for publication through the agency of the contact person set out above at 08:00 CET on October 28, 2019.